Aspiration pneumonia bacterial infection medical therapy: Difference between revisions
m (Robot: Automated text replacement (-mgibson@perfuse.org +charlesmichaelgibson@gmail.com & -kfeeney@perfuse.org +kfeeney@elon.edu)) |
m (Changes made per Mahshid's request) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Aspiration pneumonia bacterial infection}} | {{Aspiration pneumonia bacterial infection}} | ||
{{CMG}}; {{AE}} [[Priyamvada Singh|Priyamvada Singh, M.D.]] [mailto:psingh13579@gmail.com] | |||
===Medical therapy=== | ===Medical therapy=== | ||
====Antibiotics==== | ====Antibiotics==== | ||
| Line 13: | Line 14: | ||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
[[Category:Diseaase]] | [[Category:Diseaase]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Pneumonia|Pneumonia]] | [[Category:Pneumonia|Pneumonia]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Needs overview]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 17:02, 18 September 2017
|
Aspiration pneumonia bacterial infection Microchapters |
|
Differentiating Aspiration pneumonia bacterial infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Aspiration pneumonia bacterial infection medical therapy On the Web |
|
American Roentgen Ray Society Images of Aspiration pneumonia bacterial infection medical therapy |
|
FDA on Aspiration pneumonia bacterial infection medical therapy |
|
CDC onAspiration pneumonia bacterial infection medical therapy |
|
Aspiration pneumonia bacterial infection medical therapy in the news |
|
Blogs on Aspiration pneumonia bacterial infection medical therapy |
|
Directions to Hospitals Treating Aspiration pneumonia bacterial infection |
|
Risk calculators and risk factors for Aspiration pneumonia bacterial infection medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, M.D. [2]
Medical therapy
Antibiotics
- Treatment of choice clindamycin
- Doses 600 mg Q8hourly, followed by 300 mg Q6hourly, or 450 mg tid
- Advantage of clindamycin :
- Cheap
- Less incidences of superimposed MRSA
- Other agents used: Ampicillin-sulbactam (1.5 g or 3 g twice daily), Imipenem (Invanz 500 mg BID), amoxicillin-clavulnate (875 mg orally bid), penicillin (1 to 2 million units IV Q6hourly) / amoxicillin (500 mg orally tid)+ metronidazole (500 mg orally or IV tid).
- Monotherapy with metronidazole is not preferred as high failure rates have been reported. This is because metronidazole is ineffective against some pathogens such as microaerophilic and aerobic streptococci